Aquestive Therapeutics Inc (AQST)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Aquestive Therapeutics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 5 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 3.80 $ — 18% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
3/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% -1.7%
- Exp. sales growth 3Y > 5% 27.0%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 27.0%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% -61.7%
- Expected return > 10% 12.9%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -2.2% failed
- More than 10% revenue growth is expected for the coming year 42.4% passed
- Share count grows by less than 3% a year 35.8% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -141.6% failed
- Gross margin at 40% or higher and without meaningful erosion 61.5% passed
- Goodwill from acquisitions does not grow faster than revenue 0.0% passed
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 41 m failed
- Return on capital at 15% or higher, or up versus two years ago -61.7% failed
- Insiders hold at least 10% or are net buyers 3.1% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 133.9% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 9
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.42 | -0.48 – -0.36 | 51 | 28.7% | 2 |
| 12/31/2027 | -0.45 | -0.45 – -0.45 | 72 | -7.1% | 1 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.10 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.19 | – | 12 | -10.10 | -143.70 | -7 | -7 |
| 2025: Q1 | -0.24 | – | 9 | -27.70 | -263.00 | -23 | -24 |
| 2025: Q2 | -0.14 | – | 10 | -50.20 | -135.40 | -8 | -8 |
| 2025: Q3 | -0.14 | – | 13 | -5.40 | -120.60 | -13 | -13 |
| 2025: Q4 | -0.26 | – | 13 | 9.70 | -244.80 | -9 | -9 |
| 2026: Q1 | -0.07 | – | 14 | 65.70 | -55.80 | -15 | -15 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 52 | -1 | -10 | -0.39 | -8 | -18 | 39 |
| 2017 | 67 | 0 | -9 | -0.45 | 6 | -27 | 43 |
| 2018 | 67 | -49 | -61 | -2.96 | -13 | 10 | 87 |
| 2019 | 53 | -53 | -66 | -2.61 | -60 | -6 | 78 |
| 2020 | 46 | -43 | -56 | -1.66 | -45 | -49 | 63 |
| 2021 | 51 | -35 | -71 | -1.85 | -33 | -82 | 62 |
| 2022 | 48 | -42 | -54 | -1.12 | -10 | -119 | 57 |
| 2023 | 51 | -15 | -8 | -0.13 | -6 | -106 | 57 |
| 2024 | 58 | -31 | -44 | -0.51 | -36 | -60 | 101 |
| 2025 | 45 | -70 | -84 | -0.69 | -52 | -34 | 160 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Aquestive Therapeutics, Inc. ist ein Pharmaunternehmen in den USA und international.
| CEO Insider Trades (12 Mo.) | selling own stock |
|---|---|
| Employees | 147 |
| Headquarters | Warren, NJ |
| Address | 30 Technology Drive, 07059 Warren, United States |
| Phone | 908 941 1900 |
| Website | aquestive.com |
| IPO Date | 25. Jul 2018 |
| ISIN | US03843E1047 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Daniel Barber | CEO, President & Director | 1976 |
| A. Ernest Toth Jr. | Senior VP & CFO | 1959 |
| Lori J. Braender BSBA, Esq., J.D. | Corporate Secretary | 1956 |
| Cassie Jung | Chief Operating Officer | 1979 |
| Thomas A. Zalewski | Chief Legal Officer & Chief Compliance Officer | 1972 |
| Peter E. Boyd | Senior Vice President of Information Technology & Chief People Officer | 1966 |
| Matthew Greenhawt B.Sc., M.B.A., M.D. | Chief Medical Officer | 1974 |
| Sherry Korczynski | Chief Commercial Officer | 1970 |
| Melina T. Cioffi Pharm.D. | Senior Vice President of Regulatory Affairs | 1983 |
| Matthew William Davis M.D., R.Ph. | Chief Development Officer | 1966 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 16. Jul 2026 | Barber Daniel | President and CEO | Sell | 20,369 | 4.00 | 81,509 |
| 15. Jul 2026 | Barber Daniel | President and CEO | Sell | 4,631 | 4.03 | 18,683 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.